
Benchmarking Investigator Payments
If you have not read “
Industry Standard Research (ISR) recently launched a report that looked to quantify investigator payments/ grants across a number of therapeutic areas, study phases, and the types of compounds being investigated. In the “
Averages can be deceiving. The average investigator payment/ grant per patient was $6,900, but that figure can vary wildly based on the therapeutic are (e.g. Oncology), Phase (e.g. Phase I), and compound type (e.g. Biosimilar). Trial length and complexity also play a large role in the payment levels. But it is not all about the money for some investigators. Many investigators indicated they would consider taking a lower payment if they were working on a novel compound.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.